VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYNB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYNBKyntra Bio, Inc.
$2.04$15M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKYNBBalance Sheet

Kyntra Bio, Inc. (KYNB) Balance Sheet

14Y historyFree accessUpdated daily

Leverage appears elevated despite debt being reduced from $146.4M to zero, as total liabilities of $56.0M exceed total assets of $48.9M and the current ratio compressed from 3.71 to 1.16, suggesting a thin liquidity cushion.

Income StatementBalance SheetCash FlowRatios

KYNB Balance Sheet

Annual statement

KYNB Balance Sheet

Kyntra Bio, Inc. (KYNB) balance sheet — 14-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Total Current Assets48.62M99.07M196.51M331.56M492.83M474.06M755.11M702.49M690.01M748.97M266.52M200.56M198.24M143.64M52.8M
Cash & Short-Term Investments40.29M88.98M50.48M235.59M422.01M405.19M686.54M533.76M621.4M735.72M253.18M181.17M179.82M122.81M39.89M
Cash Only9.9M47.87M50.48M113.69M155.7M171.22M678.39M126.27M89.26M673.66M173.78M153.32M165.46M76.33M38.87M
Short-Term Investments30.39M41.11M0121.9M266.31M233.97M8.14M407.49M532.14M62.06M79.4M27.85M14.36M46.48M1.02M
Accounts Receivable3.85M4.22M28.98M41.05M16.3M25.4M41.88M153.66M63.68M8.45M10.45M15.4M13.45M17.5M8.78M
Days Sales Outstanding300.28238.95357.11320.1642.2739.486.7218.6109.1524.5521.2431.0935.6962.548.63
Inventory3.25M3.74M3.15M41.56M40.44M31.02M16.53M6.89M0000000
Days Inventory Outstanding344.622.46K743.83K727.7725.2680.292.19K-------
Other Current Assets1.23M1.12M111.99M6.71M4.35M5.07M1.81M1.72M4.93M4.8M2.89M3.99M4.97M00
Total Non-Current Assets231K20.52M18.02M91.97M117.26M299.76M71.73M154.91M190.58M149.68M203.04M270.01M285.29M153.31M212.78M
Property, Plant & Equipment00081.37M100.5M119.39M63.25M82.34M127.2M129.48M123.66M129.02M132.17M129.9M123.66M
Fixed Asset Turnover---0.58x1.40x1.97x2.79x3.12x1.67x0.97x1.45x1.40x1.04x0.79x0.53x
Goodwill000000000000000
Intangible Assets000000000000000
Long-Term Investments32.2M20.16M05.29M9.41M171.62M2.97M61.12M55.82M10.51M71.01M131.72M144.27M15.36M81.61M
Other Non-Current Assets231K361K18.02M5.31M7.35M8.75M5.5M11.44M7.57M9.7M8.37M9.27M8.85M8.05M7.51M
Total Assets48.85M119.59M214.53M423.53M610.09M773.82M826.84M857.4M880.6M898.65M469.55M470.57M483.53M296.95M265.59M
Asset Turnover0.06x0.05x0.14x0.11x0.23x0.30x0.21x0.30x0.24x0.14x0.38x0.38x0.28x0.34x0.25x
Asset Growth %-185.47%-44.25%-49.35%-30.58%-21.16%-6.41%-3.56%-2.63%-2.01%91.38%--2.68%62.83%11.81%-
Total Current Liabilities41.76M29.24M133.31M217.67M273.56M225.5M163.19M102.75M89.03M77.26M65.13M67.18M62.75M37.48M23.68M
Accounts Payable4.58M3.75M5.06M17.96M30.76M26.1M24.79M6.09M9.14M5.51M6.22M6.52M4.55M1.07M3.11M
Days Payables Outstanding523.972.46K118.781.65K553.5821.211.02K1.94K14.1410.2312.1311.1211.024.5415.28
Short-Term Debt00040K000983K0000403K00
Deferred Revenue (Current)22.58M5.31M27.29M12.74M12.74M19.03M6.55M490K13.77M7.97M7.99M12.73M9.22M5.74M2.39M
Other Current Liabilities35.59M3.15M70.29M152.58M7.25M4.91M95.53M63.05M44.69M17.38M36.68M34.4M5.16M2.51M2.43M
Current Ratio1.16x3.39x1.47x1.52x1.80x2.10x4.63x6.84x7.75x9.69x4.09x2.99x3.16x3.83x2.23x
Quick Ratio1.09x3.26x1.45x1.33x1.65x1.96x4.53x6.77x7.75x9.69x4.09x2.99x3.16x3.83x2.23x
Cash Conversion Cycle120.94237.64312.342.49K216.4643.4-253.19472.86-------
Total Non-Current Liabilities14.29M85.88M264.85M368.06M338M319.21M222.2M219.25M263.1M238.94M229.32M206.57M180.1M151.87M119.73M
Long-Term Debt0073.09M89.7M00000000018.86M-5.81M
Capital Lease Obligations00066.64M79.59M88.78M26.24M38.55M97.16M97.76M97.35M97.04M96.82M96.41M92.5M
Deferred Tax Liabilities000000003.04M3.66M4.21M4.7M5.13M5.5M5.81M
Other Non-Current Liabilities14.29M85.62M77.05M54.17M72.69M43.63M57.49M81.25M29.83M167.19M25.26M24.39M22.29M31.1M12.24M
Total Liabilities56.04M115.12M398.16M585.73M611.57M544.71M385.39M321.99M352.13M316.2M294.44M273.75M242.85M189.35M143.4M
Total Debt0073.09M170.46M89.89M99.72M39.76M51.89M97.16M97.76M97.35M97.04M97.22M96.81M93.23M
Net Debt-9.9M-47.87M22.61M56.77M-65.81M-71.5M-638.63M-74.38M7.9M-575.89M-76.43M-56.28M-68.23M20.48M54.36M
Debt / Equity0.00x----0.44x0.09x0.10x0.18x0.17x0.56x0.49x0.40x0.90x0.76x
Debt / EBITDA-0.00x--------------
Net Debt / EBITDA0.17x--------------
Interest Coverage-14.92x-6.66x-17.60x-38.93x-203.77x-324.21x-77.57x-25.65x-6.84x-11.42x-4.76x-7.04x-4.51x-0.74x-2.72x
Total Equity14.29M4.47M-183.63M-162.2M-1.48M229.11M441.45M535.41M528.47M582.45M175.11M196.82M240.68M107.6M122.18M
Equity Growth %262.08%102.44%-13.22%-10859.39%-100.65%-48.1%-17.55%1.31%-9.27%232.62%--18.22%123.67%-11.93%-
Book Value per Share3.531.11-45.89-41.67-0.4062.02122.82154.50157.17199.5069.773.264.192.289.28
Total Shareholders' Equity-7.19M-30.04M-225.6M-204.17M-21.45M209.15M422.18M516.13M509.2M563.18M155.84M177.55M221.41M79.73M94.48M
Common Stock41K1.01M1.01M988K942K929K914K877K854K825K637K620K590K132K132K
Retained Earnings-1.71B-1.71B-1.89B-1.84B-1.56B-1.26B-974.01M-784.72M-715.83M-595.95M-469.74M-408.06M-322.28M-262.78M-247.84M
Treasury Stock000000000000000
Accumulated OCI-1.21M-2.18M-5.73M-6.88M-5.72M-4.16M-4.5M-747K-2.28M-1.79M-960K-1.65M-3.15M-3.51M-167K
Minority Interest21.48M34.51M41.97M41.97M19.97M19.97M19.27M19.27M19.27M19.27M19.27M19.27M19.27M27.88M27.7M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Negative equity and shrinking asset base

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Deepening Negative Equity Trend

Based on reported quarterly figures, KYNB's stockholders' deficit widened from $243.7M in 2024Q3 to roughly $7.2M in 2026Q3 after first narrowing, while total assets fell from $293.2M to $48.9M over the same ten-quarter window.

The shrinking asset base alongside a volatile deficit suggests the balance sheet has been contracting rather than rebuilding, with the most recent improvement in equity likely reflecting liability reduction rather than earnings strength. Retained earnings remained near negative $1.7B to $1.9B throughout, indicating the accumulated loss history has not been meaningfully reversed. Investors should monitor whether the 2026Q3 deficit narrowing persists, as the figures alone do not establish a durable repair trajectory.

Thin Cash Buffer Against Current Obligations

As reported in the balance sheets, KYNB's current ratio compressed from 3.71 in 2025Q3 to 1.16 in 2026Q3, while cash fell to $9.9M, a level that appears thin relative to total liabilities of $56.0M.

The sharp decline in cash from $118.0M to $9.9M over four quarters, combined with a current ratio that still exceeds 1.0, suggests short-term obligations are covered on paper but with limited margin for error. Cash position relative to total liabilities implies the company may depend on near-term financing or asset monetization. This warrants further investigation, since the figures do not disclose the timing or terms of current liabilities.

Debt Retired but Leverage Remains Elevated

Based on KYNB's reported figures, total debt declined from $146.4M in 2024Q2 to zero in 2026Q3, yet the debt-to-equity ratio was last reported at 1.20 in 2025Q3 and total liabilities still exceed total assets.

Debt reduction is visible in the reported figures, but total liabilities of $56.0M against assets of $48.9M indicate the company remains in a deficit position regardless of borrowings. The reduction in debt appears to have been achieved while equity deteriorated, which may point to settlement of obligations through means other than cash. The data does not disclose the mechanism, so this interpretation warrants further investigation.

Equity Deficit Driven by Accumulated Losses

According to reported balance sheets, KYNB's equity moved from a deficit of $243.7M to $7.2M, with retained earnings consistently near negative $1.7B, reflecting an accumulated loss base that dwarfs any recent equity movement.

The scale of accumulated deficit relative to current equity suggests that the recent narrowing reflects balance sheet restructuring rather than operating profitability. Stock-based compensation and share issuance data are not provided, so dilution effects cannot be assessed from the supplied figures. The equity position appears structurally weak, and further review of capital transactions is needed.

Deferred Revenue Collapse Limits Visibility

Based on reported figures, KYNB's deferred revenue fell from $155.1M in 2024Q3 to $6.2M in 2026Q3, a decline of roughly 96%, leaving little reported contractual revenue backlog to support forward expectations.

The sharp reduction in deferred revenue suggests that previously recognized or unwound contract balances have largely run off without replacement at comparable scale. This lowers the visibility investors can draw from the balance sheet regarding future recognized revenue. Remaining performance obligations are not disclosed in the supplied data, so the full forward picture cannot be established.

Headline Equity Narrowing May Mislead

As reported in the balance sheets, KYNB's deficit compression to $7.2M rests on a $1.7B accumulated loss base, so a small equity figure may reflect liability settlement rather than a repaired capital structure.

Because retained earnings sit near negative $1.7B, the near-zero equity figure is highly sensitive to small changes in liabilities or asset valuations, meaning the 2026Q3 narrowing could reverse with modest adverse movements. Given that cash fell to $9.9M and assets shrank sharply, the apparent balance sheet improvement may be a function of reduced scale rather than enhanced financial strength. Investors should treat the headline deficit reduction as analytically fragile and warrant further investigation into the composition of remaining liabilities.

KYNB — Frequently Asked Questions

Quick answers to the most common questions about buying KYNB stock.

What are the total assets of Kyntra Bio, Inc. (KYNB)?

As of 2025, Kyntra Bio, Inc. (KYNB) had total assets of $119.6M including $99.1M in current assets.

How much debt does Kyntra Bio, Inc. (KYNB) have?

Kyntra Bio, Inc. (KYNB) carries total debt of $0.0M, offset by $89.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Kyntra Bio, Inc.?

Kyntra Bio, Inc. (KYNB) has total shareholders' equity (book value) of $-30.0M ($1.11 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Kyntra Bio, Inc.'s current ratio and liquidity?

Kyntra Bio, Inc. (KYNB) reported a current ratio of 3.39x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.